Journal
BMJ GLOBAL HEALTH
Volume 2, Issue 1, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjgh-2016-000090
Keywords
-
Categories
Funding
- Bill & Melinda Gates Foundation
- UK Medical Research Council fellowships
- Malaria Vaccine Initiative
- MRC Centre Funding + DFID
- MRC [MR/L012189/1, G1002284] Funding Source: UKRI
- Medical Research Council [MR/L012189/1, MR/K010174/1B, G1002284] Funding Source: researchfish
Ask authors/readers for more resources
Objectives: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in sub-Saharan Africa compared with further scale-up of existing interventions. Design: A mathematical modelling and cost-effectiveness study. Setting: Sub-Saharan Africa. Participants: People of all ages. Interventions: The analysis considers the introduction and scale-up of the RTS,S malaria vaccine and the scale-up of long-lasting insecticide-treated bed nets (LLINs), indoor residual spraying (IRS) and seasonal malaria chemoprevention (SMC). Main outcome measure: The number of Plasmodium falciparum cases averted in all age groups over a 10-year period. Results: Assuming access to treatment remains constant, increasing coverage of LLINs was consistently the most cost-effective intervention across a range of transmission settings and was found to occur early in the cost-effectiveness scale-up pathway. IRS, RTS,S and SMC entered the cost-effective pathway once LLIN coverage had been maximised. If non-linear production functions are included to capture the cost of reaching very high coverage, the resulting pathways become more complex and result in selection of multiple interventions. Conclusions: RTS,S was consistently implemented later in the cost-effectiveness pathway than the LLINs, IRS and SMC but was still of value as a fourth intervention in many settings to reduce burden to the levels set out in the international goals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available